{"id":714,"date":"2026-05-22T04:53:10","date_gmt":"2026-05-22T08:53:10","guid":{"rendered":"https:\/\/www.durhampeptides.ca\/post\/nad-vs-nmn-vs-nr"},"modified":"2026-06-22T14:16:40","modified_gmt":"2026-06-22T18:16:40","slug":"nad-vs-nmn-vs-nr","status":"publish","type":"post","link":"https:\/\/www.durhampeptides.ca\/fr\/post\/nad-vs-nmn-vs-nr","title":{"rendered":"NAD+ vs NMN vs NR: Comparing the NAD-Boosting Compounds for Research"},"content":{"rendered":"<figure><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-200\" src=\"https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/NAD-500mg-1.png\" alt=\"NAD+ vs NMN vs NR comparison NAD-boosting compounds research Durham Peptides Canada\" width=\"1024\" height=\"1536\" srcset=\"https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/NAD-500mg-1.png 1024w, https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/NAD-500mg-1-200x300.webp 200w, https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/NAD-500mg-1-683x1024.webp 683w, https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/NAD-500mg-1-768x1152.webp 768w, https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/NAD-500mg-1-800x1200.webp 800w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n<p>NAD+ vs NMN vs NR comparison NAD-boosting compounds research Durham Peptides Canada<\/p>\n<p><\/p>\n<p>\"NAD+ vs NMN vs NR\" is one of the most common comparison searches in longevity research, and the confusion is understandable: all three are closely related molecules in the same biosynthetic pathway, all three are studied for raising cellular NAD+, and all three are marketed under overlapping \"NAD-boosting\" language. But they are not interchangeable \u2014 they sit at different points in the pathway, and the research questions around each are distinct.<\/p>\n<p><\/p>\n<p>This article compares the three from a research perspective: what each molecule is, how they relate biochemically, and the considerations that lead researchers to choose one over another. For the foundational explainer on NAD+ itself, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/what-is-nad-plus\/\" target=\"_blank\">What Is NAD+?<\/a><\/u>.<\/p>\n<p><\/p>\n<p><strong>The Three Molecules, Defined<\/strong><\/p>\n<p><\/p>\n<p><strong>NAD+ (nicotinamide adenine dinucleotide)<\/strong> is the end product \u2014 the active coenzyme the cell actually uses in energy metabolism, sirtuin signaling, and PARP-mediated DNA repair. It's the molecule everything else in this comparison is trying to increase. Durham Peptides supplies <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/nad-500mg\/\" target=\"_blank\">NAD+ 500mg<\/a><\/u> directly.<\/p>\n<p><\/p>\n<p><strong>NMN (nicotinamide mononucleotide)<\/strong> is the immediate precursor to NAD+. In the salvage pathway, the enzyme NMNAT converts NMN into NAD+ in a single step. NMN is one molecule \"upstream\" of NAD+.<\/p>\n<p><\/p>\n<p><strong>NR (nicotinamide riboside)<\/strong> is a precursor one step further upstream than NMN. The enzyme NRK (nicotinamide riboside kinase) phosphorylates NR into NMN, which is then converted into NAD+. So the simplified pathway is: <strong>NR \u2192 NMN \u2192 NAD+.<\/strong><\/p>\n<p><\/p>\n<p><strong>The Biosynthesis Pathway at a Glance<\/strong><\/p>\n<table><tr><td><p>Molecule<\/p><\/td><td><p>Position in pathway<\/p><\/td><td><p>Conversion to NAD+<\/p><\/td><\/tr><tr><td><p>NR<\/p><\/td><td><p>Furthest upstream<\/p><\/td><td><p>NR \u2192 NMN \u2192 NAD+ (two enzymatic steps)<\/p><\/td><\/tr><tr><td><p>NMN<\/p><\/td><td><p>Immediate precursor<\/p><\/td><td><p>NMN \u2192 NAD+ (one enzymatic step)<\/p><\/td><\/tr><tr><td><p>NAD+<\/p><\/td><td><p>End product<\/p><\/td><td><p>Already the active coenzyme<\/p><\/td><\/tr><\/table>\n<p>This pathway relationship is the crux of the entire comparison. Precursor strategies (NR, NMN) rely on the cell's own enzymes to build NAD+; direct NAD+ supply provides the finished coenzyme but raises different questions about cellular uptake of a larger, charged molecule.<\/p>\n<p><\/p>\n<p><strong>The Core Research Debate: Precursor vs Direct Supply<\/strong><\/p>\n<p><\/p>\n<p>The central research question in this space is whether it's more effective to supply NAD+ directly or to supply a precursor and let the cell synthesize NAD+ itself. Each approach has a rationale studied in the literature:<\/p>\n<p><\/p>\n<p><strong>The precursor argument (NR, NMN):<\/strong> Precursors are smaller and may be taken up by cells more readily, after which the cell's own machinery converts them to NAD+ on demand. Much of the published in-vivo NAD-boosting evidence has used NR and NMN.<\/p>\n<p><\/p>\n<p><strong>The direct-supply argument (NAD+):<\/strong> Direct NAD+ supply provides the finished coenzyme without depending on the activity of the conversion enzymes, which themselves can change with age and metabolic state. Researchers studying salvage-pathway dynamics often examine direct NAD+ alongside precursors to separate uptake effects from conversion effects.<\/p>\n<p><\/p>\n<p>This is an open and active research question \u2014 not a settled one. The honest summary is that all three molecules raise cellular NAD+ in various model systems, and the relative efficiency depends heavily on tissue, model, and measurement method.<\/p>\n<p><\/p>\n<p><strong>Where 5-Amino-1MQ Fits<\/strong><\/p>\n<p><\/p>\n<p>A fourth strategy doesn't add NAD+ or a precursor at all \u2014 it reduces the <em>loss<\/em> of NAD+ building blocks. Durham Peptides' <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/5-amino-1mq-10mg\/\" target=\"_blank\">5-Amino-1MQ<\/a><\/u> is an NNMT inhibitor. NNMT methylates nicotinamide and diverts it away from the NAD+ salvage pathway; inhibiting NNMT is studied as a way to preserve the nicotinamide pool available for NAD+ resynthesis. Researchers sometimes study salvage-pathway preservation (NNMT inhibition) alongside direct supply (NAD+) as complementary mechanisms.<\/p>\n<p><\/p>\n<p><strong>What Durham Peptides Carries<\/strong><\/p>\n<p><\/p>\n<p>Durham Peptides stocks <strong>NAD+ directly<\/strong> (<u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/nad-500mg\/\" target=\"_blank\">NAD+ 500mg<\/a><\/u>) and the salvage-pathway modulator <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/5-amino-1mq-10mg\/\" target=\"_blank\"><strong>5-Amino-1MQ<\/strong><\/a><\/u>. The catalog does not currently include NMN or NR. For researchers whose protocol calls specifically for NAD+ or for salvage-pathway modulation, these two compounds cover the direct-supply and salvage-preservation strategies. For protocols requiring NMN or NR specifically, those would need to be sourced separately.<\/p>\n<p><\/p>\n<p><strong>How Researchers Choose<\/strong><\/p>\n<p><\/p>\n<p>The choice among these molecules in a research protocol typically comes down to the specific question being asked:<\/p>\n<ul><li><strong>Studying the active coenzyme directly, or salvage-pathway dynamics<\/strong> \u2192 NAD+ (and optionally 5-Amino-1MQ for NNMT modulation).<\/li><li><strong>Studying precursor uptake and cellular conversion<\/strong> \u2192 NMN or NR.<\/li><li><strong>Studying the full pathway<\/strong> \u2192 potentially all of them, in parallel arms.<\/li><\/ul>\n<p><\/p>\n<p>No single molecule is \"best\" in the abstract; the right choice is dictated by the experimental design. What's consistent across all of them is the need for verified purity and identity, since NAD-pathway readouts are sensitive to contaminants.<\/p>\n<p><\/p>\n<p><strong>Questions fr\u00e9quentes<\/strong><\/p>\n<p><\/p>\n<p><strong>What is the difference between NAD+, NMN, and NR?<\/strong> NAD+ is the active coenzyme. NMN is its immediate precursor (one enzymatic step away). NR is a precursor one step further upstream (NR \u2192 NMN \u2192 NAD+).<\/p>\n<p><\/p>\n<p><strong>Which is better, NAD+, NMN, or NR?<\/strong> There's no settled answer \u2014 it depends on the research question and model system. All three are studied for raising cellular NAD+, and the relative efficiency varies by tissue and method.<\/p>\n<p><\/p>\n<p><strong>Is NMN or NR more effective than taking NAD+ directly?<\/strong> This is an open research question. Precursors may have uptake advantages; direct NAD+ supply bypasses the conversion enzymes. Researchers often compare them directly.<\/p>\n<p><\/p>\n<p><strong>Does Durham Peptides sell NMN or NR?<\/strong> Not currently. Durham Peptides stocks <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/nad-500mg\/\" target=\"_blank\">NAD+ 500mg<\/a><\/u> directly and the NNMT inhibitor <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/5-amino-1mq-10mg\/\" target=\"_blank\">5-Amino-1MQ<\/a><\/u>.<\/p>\n<p><\/p>\n<p><strong>What is the NAD+ salvage pathway?<\/strong> The pathway that recycles nicotinamide back into NAD+. NMN is a key intermediate; NNMT (inhibited by 5-Amino-1MQ) diverts nicotinamide away from it.<\/p>\n<p><\/p>\n<p><strong>Are NAD+, NMN, and NR peptides?<\/strong> No. All three are nucleotide-related molecules, not peptides. They're studied alongside research peptides for their metabolic and longevity relevance.<\/p>\n<p><\/p>\n<p><strong>Final Thoughts<\/strong><\/p>\n<p><\/p>\n<p>NAD+, NMN, and NR are three points on the same pathway, and the \"vs\" framing oversimplifies what is really a question of experimental design: are you studying the active coenzyme, a precursor's uptake and conversion, or the pathway as a whole? For researchers working with the active coenzyme directly or studying salvage-pathway dynamics, Durham Peptides supplies <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/nad-500mg\/\" target=\"_blank\">NAD+ 500mg<\/a><\/u> and the NNMT inhibitor <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/5-amino-1mq-10mg\/\" target=\"_blank\">5-Amino-1MQ<\/a><\/u>, both Janoshik-verified.<\/p>\n<p><\/p>\n<p>For the foundational science, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/what-is-nad-plus\/\" target=\"_blank\">What Is NAD+?<\/a><\/u>. For the buying decision, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/buy-nad-plus-canada\/\" target=\"_blank\">Buy NAD+ in Canada<\/a><\/u>.<\/p>\n<p><\/p>\n<p><strong>Selected Research References<\/strong><\/p>\n<p><\/p>\n<ol><li>Yoshino J, Baur JA, Imai SI. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. <em>Cell Metabolism<\/em>. 2018;27(3):513-528. <u><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29211728\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/29211728\/<\/a><\/u><\/li><li>Rajman L, Chwalek K, Sinclair DA. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. <em>Cell Metabolism<\/em>. 2018;27(3):529-547. <u><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29295624\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/29295624\/<\/a><\/u><\/li><li>Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ Metabolism and Its Roles in Cellular Processes During Ageing. <em>Nature Reviews Molecular Cell Biology<\/em>. 2021;22(2):119-141. <u><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33353981\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/33353981\/<\/a><\/u><\/li><li>Verdin E. NAD+ in Aging, Metabolism, and Neurodegeneration. <em>Science<\/em>. 2015;350(6265):1208-1213. <u><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25540137\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/25540137\/<\/a><\/u><\/li><\/ol>\n<p><\/p>\n<p><em>All products sold by Durham Peptides are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.<\/em><\/p>","protected":false},"excerpt":{"rendered":"NAD+ vs NMN vs NR comparison NAD-boosting compounds research Durham Peptides Canada \"NAD+ vs NMN vs NR\" is one of the most common comparison searches in longevity research, and the confusion is understandable: all three are closely related molecules in the same biosynthetic pathway, all three are studied for raising cellular NAD+, and all three are marketed under overlapping \"NAD-boosting\" language. But they are not interchangeable \u2014 they sit at different points in the pathway, and the...","protected":false},"author":1,"featured_media":200,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55],"tags":[],"class_list":["post-714","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research-science"],"_links":{"self":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts\/714","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/comments?post=714"}],"version-history":[{"count":1,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts\/714\/revisions"}],"predecessor-version":[{"id":1055,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts\/714\/revisions\/1055"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/media\/200"}],"wp:attachment":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/media?parent=714"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/categories?post=714"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/tags?post=714"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}